

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**CHANGES OF CHIEF EXECUTIVE OFFICER, DIRECTORS,  
BOARD COMMITTEE MEMBERS  
AND  
AUTHORIZED REPRESENTATIVE**

The Board announces that, with effect from 14 January 2022:

- (1) In order to comply with the code provision C.2.1 of the Corporate Governance Code as set out in Appendix 14 to the Listing Rules that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual and to devote more time and attention to approve and monitor the Group's strategies and policies, Mr. Han Yuewei has resigned and ceased to be the chief executive officer, the chairman of the executive committee, a member of the corporate governance committee and an authorized representative of the Company and has been re-designated as a non-executive director of the Company and will continue to serve as the chairman of the Board and chairman of the nomination committee of the Company;
- (2) Mr. Bai Xiaosong has been appointed as an executive Director, the chief executive officer, the chairman of the executive committee, a member of the corporate governance committee and an authorized representative of the Company;
- (3) Mr. Qing Mei Ping Cuo has resigned as a non-executive director and a member of the audit committee of the Company due to other work arrangements; and
- (4) Mdm. Jiao Ruifang has been appointed as a non-executive director and a member of the audit committee of the Company.

## CHANGES OF CHIEF EXECUTIVE OFFICER, DIRECTOR, BOARD COMMITTEE MEMBERS AND AUTHORIZED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from 14 January 2022:

- (1) In order to comply with the code provision C.2.1 of the Corporate Governance Code as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (“**Listing Rules**”) that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual and to devote more time and attention to approve and monitor the Group’s strategies and policies, Mr. Han Yuewei (“**Mr. Han**”) has resigned and ceased to be the chief executive officer, the chairman of the executive committee, a member of the corporate governance committee and an authorized representative of the Company and has been re-designated as a non-executive director of the Company and will continue to serve as the chairman of the Board and chairman of the nomination committee of the Company;
- (2) Mr. Bai Xiaosong (“**Mr. Bai**”) has been appointed as an executive Director, the chief executive officer, the chairman of the executive committee, a member of the corporate governance committee and an authorized representative of the Company;
- (3) Mr. Qing Mei Ping Cuo (“**Mr. Qing Mei**”) has resigned as a non-executive director and a member of the audit committee of the Company due to other work arrangements; and
- (4) Mdm. Jiao Ruifang (“**Mdm. Jiao**”) has been appointed as a non-executive director and a member of the audit committee of the Company.

Mr. Qing Mei has confirmed that he has no disagreement with the Board and there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Qing Mei for his invaluable contributions to the Group and the Board.

The biographical details of Mr. Han, Mr. Bai and Mdm. Jiao are set out as follows:

**Mr. Han Yuwei**, aged 53, currently serves as an executive vice president of China Resources (Holdings) Company Limited. Mr. Han was appointed as an executive Director, chief executive officer, chairman of the executive committee, member of the corporate governance committee and authorized representative of the Company in October 2019, and was appointed as chairman of the Board and the chairman of the nomination committee of the Company in December 2021. Mr. Han ceased to be the chief executive officer, chairman of the executive committee, member of the corporate governance committee and authorized representative of the Company and was re-designated as a non-executive director and will continue to serve as the chairman of the Board and chairman of the nomination committee of the Company with effect from 14 January 2022. He also serves as a director of China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司)(the shares of which are listed on the Shenzhen Stock Exchange (Stock Code: 000999)) (“**CR Sanjiu**”) and a director of China Resources Double-Crane Pharmaceutical Company Limited (華潤雙鶴藥業股份有限公司)(the shares of which are listed on the Shanghai Stock Exchange, Stock Code: 600062) (“**CR Double-Crane**”). Mr. Han served as an executive director of China Resources Medical Holdings Company Limited (“**CR Medical**”) (the shares of which are listed on The Stock Exchange, stock code: 1515) from October 2017 to October 2019, during which he served as the chief executive officer of CR Medical and the general manager of China Resources Healthcare Group Limited, the controlling shareholder of CR Medical. Mr. Han worked for China Resources Land Limited (“**CR Land**”) (the shares of which are listed on the Stock Exchange, stock code: 1109) from October 2010 to October 2017, during which he served as deputy general manager of Shenyang Region, deputy general manager of Shenzhen Region, director of engineering and vice president of CR Land. Prior to joining CR Land, Mr. Han worked as the deputy director and director of the Bureau of Public Works of Shenzhen Municipality (深圳市建築工務署) from April 2002 to October 2010. Mr. Han obtained a master’s degree in construction economics and management from Tsinghua University (清華大學) and a bachelor’s degree in construction management from Tsinghua University in July 1993 and July 1991 respectively.

There is no service contract entered into between Mr. Han and the Company for his position as a non-executive Director. Mr. Han will be subject to retirement by rotation and re-election at the annual general meeting pursuant to the articles of association of the Company. Mr. Han will not receive any director’s emolument from the Company.

As at the date of this announcement, Mr. Han beneficially owned 300,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Securities and Futures Ordinance**”), representing less than 0.01% of the issued share capital of the Company. Save as disclosed above, as at the date of this announcement, Mr. Han does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Han (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) currently does not hold any other position in the Company or any of its subsidiaries; (iii) did not hold any other directorship in public companies listed in Hong Kong or overseas in the last three years; (iv) does not have any other matters in relation to their appointments that need to be brought to the attention of the holders of the securities of the Company; and (v) there is no other information which is required to be disclosed pursuant to any requirements of Rule 13.51(2) of the Listing Rules.

**Mr. Bai Xiaosong**, aged 50, served as a vice president of CR Sanjiu from June 2021 to December 2021. Mr. Bai served as an assistant general manager of China Resources Snow Breweries (China) Co., Ltd. (華潤雪花啤酒(中國)有限公司) (“**CR Snow Breweries**”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd. (沈陽華潤三洋壓縮機有限公司), a senior analyst and a sales director of China Resources (Holdings) Company Limited. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.

There is no service contract entered into between Mr. Bai and the Company for his position as an executive Director. Mr. Bai shall hold office until the next general meeting of the Company after his appointment and shall then be eligible for re-election at such meeting. Thereafter, Mr. Bai shall be subject to retirement by rotation at least once every three years at the annual general meeting pursuant to the articles of association of the Company. Mr. Bai will not receive any director's emolument from the Company. His remuneration as an executive Director and the chief executive officer of the Company will be determined with reference to his position and level of responsibilities, the remuneration policy of the Company and the prevailing market conditions. The remuneration payable to Mr. Bai is subject to review by the Board from time to time pursuant to the power given to it under the articles of association of the Company and authorization from the Shareholders at annual general meeting.

As at the date of this announcement, Mr. Bai beneficially owned 200,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, representing less than 0.01% of the issued share capital of the Company. Saved as disclosed above, as at the date of this announcement, Mr. Bai does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Bai (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) currently does not hold any other position in the Company or any of its subsidiaries; (iii) did not hold any other directorship in public companies listed in Hong Kong or overseas in the last three years; (iv) does not have any other matters in relation to their appointments that need to be brought to the attention of the holders of the securities of the Company; and (v) there is no other information which is required to be disclosed pursuant to any requirements of Rule 13.51(2) of the Listing Rules.

**Mdm. Jiao Ruifang**, aged 44, joined the Beijing State-owned Capital Operation and Management Company Limited (formerly known as the Beijing State-Owned Capital Operation And Management Center) (the “**BSCOMC**”) in 2014 and is currently the general manager of the capital operation department of the BSCOMC and a non-independent director of Beijing Urban-Rural Commercial (Group) Co., Ltd. (北京城鄉商業(集團)股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600861). Mdm. Jiao served as the board secretary of Beiren Printing Machinery Holdings Limited (北人印刷機械股份有限公司), the board secretary of Beijing Jingcheng Machinery Machinery Electric Company Limited (北京京城機電股份有限公司) and the deputy general manager of Beijing Tianhai Industrial Co., Ltd. (北京天海工業有限公司). Mdm. Jiao holds an MBA in Finance from The Chinese University of Hong Kong-Tsinghua University.

There is no service contract entered into between Mdm. Jiao and the Company for her position as a non-executive Director. Mdm. Jiao shall hold office until the next general meeting of the Company after her appointment and shall then be eligible for re-election at such meeting. Thereafter, Mdm. Jiao shall be subject to retirement by rotation at least once every three years at the annual general meeting pursuant to the articles of association of the Company. Mdm. Jiao will not receive any director's emolument from the Company.

As at the date of this announcement, Mdm. Jiao does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mdm. Jiao (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) currently does not hold any other position in the Company or any of its subsidiaries; (iii) did not hold any other directorship in public companies listed in Hong Kong or overseas in the last three years; (iv) does not have any other matters in relation to their appointments that need to be brought to the attention of the holders of the securities of the Company; and (v) there is no other information which is required to be disclosed pursuant to any requirements of Rule 13.51(2) of the Listing Rules.

The Board hereby extends its gratitude to Mr. Han, Mr. Bai and Mdm. Jiao for their new appointments.

Saved as disclosed above, the Board is not aware of any other matters relating to the aforesaid appointments that need to be brought to the attention of the shareholders of the Company and any other information that should be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

Following the above changes, Mr. Han continues to serve as the chairman of the Board and the chairman of the nomination committee and has been re-designated as a non-executive director of the Company. The Board expresses its heartfelt gratitude to Mr. Han for his diligence and contributions during his tenure as the chief executive officer of the Company.

Reference is made to the announcement of the Company dated 3 December 2021 in relation to, among other things, the deviation of the Company from code provision C.2.1 (formerly code provision A.2.1) of the Corporate Governance Code as set out in Appendix 14 to the Listing Rules that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Following the above change of chief executive officer of the Company, the Company has fully complied with the requirement under code provision C.2.1 of Appendix 14 to the Listing Rules.

By Order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Shenzhen, 14 January 2022

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mdm. Weng Jingwen and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mr. Tan Ying, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*